Search Results

AMO Pharma Limited provided an update on plans to advance the clinical development program for AMO-02, the company’s investigational therapy in development for the treatment of Type 1 myotonic dystrophy, following a recent meeting with the U.S. Food and Drug Administration.

AMO Pharma Limited announced a collaboration with Population Health Research Institute, a joint institute of McMaster University and Hamilton Health Sciences in Canada, to advance a clinical proof of concept trial to assess the efficacy of AMO-02, AMO Pharma’s investigational oral glycogen synthase kinase 3 beta inhibitor, in the treatment of genotype positive arrhythmogenic cardiomyopathy.

AMO Pharma Limited (“AMO Pharma”) today announced initial preclinical data from a study of the use of the company’s investigational therapy AMO-02 in the treatment of Duchenne muscular dystrophy (DMD).

AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, announced results from the company’s REACH-CDM clinical study of the investigational therapy AMO-02 in the treatment of children and adolescents with congenital myotonic dystrophy.

AMO Pharma Limited announced completion of treatment for the final patient enrolled in the company’s REACH-CDM clinical study of the investigational therapy AMO-02.

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.

A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.

Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.

AMO Pharma Limited announced completion of patient enrollment in the company’s REACH-CDM study of the investigational therapy AMO-02 in treatment of congenital myotonic dystrophy.

AMO Pharma Limited announced that the UK Medicines and Healthcare products Regulatory Agency has confirmed that the Congenital DM1 Rating Scale can be considered an approvable primary outcome measure in clinical trials to develop a treatment for congenital myotonic dystrophy type 1.